number, and course of regimens, and survival after OC using Kaplan-Meier method were analyzed. There were 12 males and 6 females with a median age of 59 (range 13-83) years. Histological subtypes were 13 osteosarcomas, 2 MFHs, and 3 others, and all patients except one had metastasis. The median follow-up period after OC was 10.7 (1.2-135.3) months. Results: Median period from first visit to OC was 23.7 months. OC was performed as first line in 1, second line in 9, and third line in 8. Median regimens and courses of OC were 1(1-4) and 4.5 (1-30), respectively. OC regimens included CBDCA/ETP (median 9 (3-17) courses) in 11, GEM/DTX (median 2 (1-4) courses) in 7, THP (median 2.5 (1-18) courses) in 6, and DXR (median 1 (1-2) courses) in 3. Additional treatments were radiation in 7, surgery in 2, and carbon ion radiotherapy in 1. Median survival after OC was 19.8 months in 15 patients without radical treatments. Three patients were treated with surgery or carbon ion radiotherapy, and 2 of them survived 9 years or longer. Conclusion: Metastatic bone sarcoma patients are known to have poor survival. OC is a desirable treatment for them because daily life can be maintained, but approved drugs are few in Japan. In our study, survival after OC was acceptable even for patients without radical treatments, and the regimen of CBDCA/ETP was usable for a long time. OC may thus be a good treatment option for advanced bone sarcoma patients.
Background: The achievement of optimal treatment response in oncology is in conjunction with multi-agent chemotherapeutic drugs, individualized multi-disciplinary treatment plan, and management of treatment-related complications. Medical institutions had paid attention to the medication error via the management of the Medication Administration Information System (MAIS) to improve the accuracy and to shorten the working time of the medication process. Most studies point out MAIS helps teamwork coordination and management. It rarely referred to patterns of knowledge of the teamwork coordination and management from the user experience. This study was to explore patterns of knowing and values with the implementation of a MAIS in oncology wards of hospitals in Taiwan. Methods: The field observation and in-depth interview were used from November 2017 to February 2018. The interview with fifteen users (two head nurses, seven clinical nurses, two health informatics specialists, two doctors, and two pharmacists), who experienced the traditional medication administration system and the MAIS in oncology, was focused on their perspective, feeling, and implication. Results: MAIS was developed in the progressive impression of technology more than the analysis of nursing behaviors at the medication error. Most disciplinary practices were for nurses whether the system was useful for users or not. Therefore, the nurses choose to depend on the MAIS instead of awareness of professional judgment to avoid the challenge when they provided the medication administration. Conclusion: It is controversial whether technology always comes from human nature, especially the relationship among knowledge, MAIS, and human nature. The professional role of nursing must depend on the MAIS. It is worth discussing that what the role of MAIS is in the medication administration process of nursing. Some suggestions are proposed to the nursing practice, the education and the policy. Background: NUT midline carcinoma (NMC) is a highly lethal tumor genetically defined by the presence of NUTM1 rearrangements. The diagnostic reagents are not available in most hospitals, and NMC is frequently misdiagnosed as poorly differentiated squamous cell carcinoma or other histological cancer types. Since NMC does not arise from any specific organ, awareness of NMC should be raised among oncologists and multi-disciplinary approach in the diagnosis is needed. The actual prevalence of NMC is unknown in Japan, and its genetic features and targeted therapy remain poorly described.
Objective: We intended to assess its prevalence and reveal genetic features, and to predict drug sensitivity of NMC.
Methods: We used QuantStudio 3D dPCR system (Thermo Fisher Scientific) and designed optimal digital PCR (dPCR) probes to detect BRD-NUT fusion genes in clinical tumor samples. Ion AmpliSeq comprehensive cancer panel was used in next-generation sequencing (Ion PGM, Thermo Fisher Scientific) to identify genetic mutations in NMC cell lines and tumors from patients with NMCs. Drug sensitivity of NMC lines was assessed with comprehensive drug screening panel consisting of more than 300 drugs (Screening Committee of Anticancer Drugs). Results: We identified the patients whose tumors had the BRD-NUT fusion genes using dPCR assay. The genetic analysis revealed that NMC lines and tumors from the patient with NMC had FGFR3 tyrosine kinase domain mutations. Interestingly, the drug screening tests showed that NMC lines were rather resistant to FGFR inhibitors, while they were sensitive to mTOR inhibitors. Conclusion: NMC is rare and has poor prognosis. Further study is needed to improve survival outcomes.
O3 À 7 À 4 A 10-year population-based study of the differences between NECs and carcinomas of the esophagus NECs, 6,102 SCCs and 10,848 ACs, were analyzed. ACs showed an obviously higher prevalence than the other two tumor types, and the prevalence of NECs was increasing. NECs were associated with an obviously worse survival than ACs (log-rank test, P<0.01). Most NECs were poorly differentiated and had an obviously higher percentage of metastasis. NECs and ACs often metastasized to the liver (29.41% and 23.11%, respectively), while SCCs typically metastasized to the lung (15.84%) and distant lymph nodes (15.37%). We divided the patients into two groups for further analysis according to the metastasis status. For NECs, no benefit was obtained by surgery in metastatic disease. For SCCs and ACs, surgery of the primary sites produced survival benefits in both groups, but the benefits of lymphadenectomy and metastasis dissection need further study.
Conclusion: NECs of the esophagus have the worst prognosis compared to SCCs and ACs from the same period. Radical surgery provides limited benefits to patients diagnosed with NECs, so systemic treatments should be considered instead of surgical procedures. A unique guideline with a new staging and grading system for esophageal NECs is urgently needed.
O3 À 11 À 1 Phase II trial of neoadjuvant S-1 and concurrent radiotherapy for borderline resectable pancreatic cancer (JASPAC05)
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